Hackathon Judges

Joy Allen

Chair, Berklee's Music Therapy Department; Acting Director, Music and Health Institute

Joy Allen joined Berklee as chair of the Music Therapy Department in August 2016. She is an accomplished clinician, supervisor, researcher, teacher, and administrator with extensive experience in psychological health, pain management, and the family system.

Allen has expertise working with children, adolescents, and adults with mental health issues, applying a family systems approach. She is particularly passionate about working with individuals and families facing chronic illnesses, including cancer. Her current research interests include quantitative analysis of the effects of music therapy on the psychological health of medical patients, guided imagery and music with medical patients, and medical music therapy theory development and efficacy. She comes to Berklee from Loyola University in New Orleans, where she served as coordinator of music therapy and associate professor.

Yumin Choi

Partner, Bain Capital

Yumin Choi joined Bain Capital Ventures in 2017 and leads its healthcare team. He is based in Boston and invests across venture and growth stages. Choi was previously general partner at HLM Venture Partners, a health care–focused venture fund. He spent 10 years at HLM, where he led a variety of investments across the health care IT and services sectors. He has served as board director for AbleTo, mPulse Mobile, Oceans Healthcare, Payspan (acquired by Primus Capital), Spinal Kinetics, and Vets First Choice. He was also board observer for Imagine Health, Nordic Consulting (acquired by Silversmith Capital Partners), Persivia, and TYRX (acquired by Medtronic).

Choi serves on the board of trustees for Newton-Wellesley Hospital and Mass. Eye and Ear. He is on the New England Venture Capital Association’s board of directors and was previously chair of New England Venture Network. He is also on the board of advisors for the Boston Symphony Orchestra. He has served as a lecturer at the Gordon Institute at Tufts University, where he taught entrepreneurial finance.

Born in Seoul, South Korea, Choi moved to Hawaii at the age of 10, where he attended Punahou School. Outside of work, he enjoys golfing, fly fishing, and bird hunting, and can be found listening to his vinyl record collection. He received his B.S. in entrepreneurship and finance at Babson College.

Zen Chu

Cofounder and Lead Faculty Advisor, MIT Hacking Medicine Institute

Zen Chu believes that now is the best time in history for health care entrepreneurs and engineers to create the technology-enabled products and services to help medicine scale and serve more patients with higher quality at lower cost.

Chu created the MIT Hacking Medicine Institute and the MIT-Harvard Healthcare Ventures entrepreneurship courses, founded four medical technology companies, and has been the first investor in many high-growth medical technology and digital health companies through Accelmed Ventures.

Previously, Chu managed and led new ventures for Harvard Medical School, Harvard’s Wyss Institute for Bioengineering, NetVentures, and Hewlett Packard.

Lori F. Gooding

Assistant Professor, Music Therapy, Florida State University College of Music

Lori Gooding, Ph.D., MT-BC, is an assistant professor of music therapy at Florida State University. Her clinical background includes music therapy in mental and physical health care, and her research has focused on music therapy in psychosocial care, patient-and family-centered care in music therapy, and music therapy education.

Gooding's publications appear in journals like the Journal of Music Therapy and Music Therapy Perspectives, and she is a member of the board of directors for the American Music Therapy Association. Gooding has presented nationally and internationally, and currently serves on the editorial board for the Journal of Music Therapy. She has also received research grants from organizations like the AARP, the National Institute on Aging, the Florida Division of Cultural Affairs/National Endowment for the Arts, and the Awesome Foundation.

David Hutchinson

General Counsel and Head of Legal Business Partners, MilliporeSigma

David Hutchinson is general counsel for MilliporeSigma, a leading global supplier to the life science industry of solutions and services for research, development, and production of biotechnology and pharmaceutical drug therapies. At MilliporeSigma, Hutchinson oversees all legal issues related to the development and implementation of the company’s business strategy, corporate governance, human resources, general commercial matters, and litigation (excluding patents and compliance). 

Hutchinson joined the organization in 2005 via Millipore as assistant general counsel, providing legal support for acquisitions, alliances, public securities compliance and reporting, corporate financing, governance, and general commercial operations. Previously, he was a partner in the corporate departments of several Boston law firms, including Choate Hall & Stewart, where he counseled both publicly and privately held corporations in the areas of corporate law, corporate finance, securities law, mergers and acquisitions, and venture capital. He began his career in finance, working primarily as financial manager for Digital Equipment Corporation (later the Hewlett Packard Company). 

Hutchinson received his Juris Doctor degree from Boston University's School of Law and a Bachelor of Science in economics from the University of Pennsylvania's Wharton School with concentrations in finance and international business.

Jason Rhodes

Partner, Atlas Venture

Jason Rhodes is a partner at Atlas Venture and focuses on the creation, development, and business strategy of novel therapeutics companies. He is a founder and the chairman, and previously acting CEO, of Generation Bio, and a founder, the chairman, and currently acting CEO of Disarm Therapeutics. He's also a member of the board of directors of Replimune, Gemini Therapeutics, Accent Therapeutics, and Bicycle Therapeutics.

Prior to joining Atlas in 2014, Rhodes was president of Epizyme, a public biopharmaceutical company. Prior to Epizyme, he led business development at Alnylam Pharmaceutical. Prior to Alnylam, he was a founder and partner with Fidelity Biosciences (now F-Prime Capital Partners), the life sciences venture capital arm of Fidelity Investments. He holds a B.A. from Yale University and an M.B.A. from the Wharton School at the University of Pennsylvania.